First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...
The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
Zytiga is one of the most important growth products for J&J, with worldwide sales of the drug in the first half of the year growing more than 38 per cent to reach $464m. Link NICE says no to early ...
Medpage Today on MSN6d
End of the Road for Immune Checkpoint Inhibitors in Prostate Cancer?About 54% had prior abiraterone (Zytiga) and 45% had previously received enzalutamide (Xtandi). About half of the patients ...
The first patient has been dosed in a phase 1b/2a trial (NCT06785636) of pocenbrodib, a CBP/p300 inhibitor, as a monotherapy and in combination with abiraterone acetate (Zytiga), olaparib (Lynparza), ...
Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...
Blue chip stocks are from well-established companies with reliable profit records. They offer stable dividends and are favored for long-term investment security. Diversifying portfolios with blue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback